Matthew Kulke, MD, director, Program in Neuroendocrine and Carcinoid Tumors, Dana-Farber Cancer Institute, chair, North American Neuroendocrine Tumor Society (NANETS), comments on some unanswered questions surrounding the treatment of neuroendocrine tumors (NETs).
It is encouraging that new treatments exist to help patients with NETs, Kulke says, but questions remain regarding their best use — the appropriate combination and sequence is likely different for every patient.
A larger question, Kulke says, concerns the underlying molecular drivers of NETs. This area is just beginning to be understood with the help of genomic and proteomic studies. As the growth of NETs is fully understood, researchers can be smarter about developing drugs.
<<< View more from NANETS